HeartForce introduced the Electromechanical Risk (EMR) Score at the prestigious CinC2023 conference held in Atlanta. Computing in Cardiology Conference, a globally recognized scientific symposium, provides a platform for experts in the fields of medicine, physics, engineering, and computer science to disseminate their cutting-edge research in clinical cardiology and cardiovascular physiology. The EMR Score’s debut at… Continue reading EMR Score Introduced at the Computing in Cardiology Conference
Author: Nicholas Jessel
HeartForce presents CardioClin 3.0
Hearforce’s design team optimized the next generation of CardioClin which featured a more ergonomic shape and improved usability. The narrower shape allows a better fit for both female and male users. The small disposable electrode patch lets the sensor be easy to apply and sanitize.
Finalization of HeartForce proprietary EMR-Score-Algorithm
HeartForce has developed the Electromechanical Risk (EMR) Score, a groundbreaking AI-powered tool for precise cardiac risk assessment in coronary artery disease (CAD) screening. Leveraging seismocardiography (SCG) data and clinical variables, the EMR Score offers a non-invasive, data-driven approach to screen CAD risk. The use of SCG enhances patient comfort and convenience during screening. The EMR… Continue reading Finalization of HeartForce proprietary EMR-Score-Algorithm
Finalizing AFib Algorithm
Heartforce’s Afib detection algorithm was tested on a large database of 84k cases with an accuracy equivalent to current FDA approved algorithms. Afib detection will be deployed on future CardioClin and CardioPro products and will be ready for Health Canada and FDA submissions.
HeartForce starts Phase 1 of Verification Study in Uzbekistan
HeartForce has embarked on Phase 1 of a Verification Study in Uzbekistan. This significant undertaking follows the successful development of the EMR Score in a prior study. In this new phase, HeartForce is in the process of acquiring a comprehensive verification database, meticulously designed to closely resemble the characteristics of the actual target population. This… Continue reading HeartForce starts Phase 1 of Verification Study in Uzbekistan
HeartForce files new provisional patent in the US
HeartForce filed a patent application in the United States for monitoring patients after coronary angioplasty. The provisional patent was assigned the application number U.S. 63/459960. Meanwhile, the company will be conducting a one-year clinical study through the monitoring patients pre and post stent surgery
Need to get in touch with the team? We’re all ears.
Contact us today.
This website (“Web Site”) is offered to you by HeartForce Medical Inc. (HeartForce), Vancouver, BC, Canada.
The following Terms of Use govern your access and use of this Web Site and its service. Also, specific terms and conditions may apply to specific content, data, materials, or information contained on or available through this Web Site (the “Content”) and to specific content, data, materials, or information you may upload, submit and/or publish to the Web Site (“User Content”) or transactions concluded through this Web Site.
The following Terms of Use govern your access and use of this Web Site and its service. Also, specific terms and conditions may apply to specific content, data, materials, or information contained on or available through this Web Site (the “Content”) and to specific content, data, materials, or information you may upload, submit and/or publish to the Web Site (“User Content”) or transactions concluded through this Web Site.